Pfizer, Summit Therapeutics

Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown
Summit Therapeutics, Inc. shares rebounded in after-hours trading on Monday after a 14% selloff during regular hours, with retail sentiment surging on news of a major clinical trial collaboration with Pfizer.
Summit Therapeutics announces clinical trial collaboration with Pfizer
Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc.
Akeso's Partner Summit, Pfizer Collaborate To Evaluate Ivonescimab In Solid Tumor Settings
Akeso Inc. has announced that Summit Therapeutics Inc. (SMMT), its partner for ivonescimab, has entered into a clinical trial
Summit Therapeutics jumps 5% to $23.19 after trial pact with Pfizer
EST Summit Therapeutics (SMMT) jumps 5% to $23.19 after trial pact with Pfizer (PFE)Discover the Best Stocks and Maximize Your Portfolio:
Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos
Summit on Monday said the companies plan to evaluate ivonescimab in combination with several Pfizer ADCs across multiple solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations.
Pfizer: What The Summit Therapeutics Deal Brings
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why PFE stock is a Buy.
Is Summit Therapeutics (SMMT) One of the Best Growth Stocks to Invest In According to Analysts?
We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...
FierceBiotech18h
Pfizer to test Summit's white-hot bispecific with ADCs
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.
BioPharma Dive13h
Summit partners with Pfizer to study bispecific, ADC combinations
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Summit Therapeutics Shares Down as 4Q Loss Widens
Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter. Shares were trading 14% lower at $19.11. The biopharmaceutical oncology company reported a loss of $61.2 ...
Insider Stock Buying Reaches US$78.8m On Summit Therapeutics
Over the last year, a good number of insiders have significantly increased their holdings in Summit Therapeutics ...
Summit Therapeutics reports Q4 EPS (7c), consensus (6c)
Aggregate cash and cash equivalents and short-term investments were $412.3M and $186.2M at December 31, 2024 and December 31, 2023, ...
CIBC Asset Management Inc Has $385,000 Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)
CIBC Asset Management Inc lifted its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 5.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 21,577 shares of ...